Epidemiology and management of childhood multidrug-resistant tuberculosis

Clinical Practice

Volumn 9, Issue 6, 2012, Pages 701-713

  Schaaf, H Simon ^a,b   Seddon, James A ^a,c  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

ABDOMINAL PAIN; ANTIMICROBIAL THERAPY; ARTHRALGIA; ARTHRITIS; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BODILY SECRETIONS; BONE MARROW SUPPRESSION; CHILD; CHILD HEALTH; DIARRHEA; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SENSITIVITY; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HALLUCINATION; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; HYPOKALEMIA; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIVER DISEASE; MENTAL DISEASE; METALLIC TASTE; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OPTIC NEURITIS; OTOTOXICITY; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHENOTYPE; POPULATION RESEARCH; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; SKIN DISCOLORATION; SKIN TOXICITY; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TASTE DISORDER; TREATMENT DURATION; TUBERCULOSIS CONTROL; XEROSIS;

EID: 84870222108     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/cpr.12.62     Document Type: Review

References (87)

1. Zhang Y, Yew W W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13(11), 1320-1330 (2009).
2. Bergval IL, Schuitema AR, Klatser PR, Anthony RM. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not refect the in vivo mechanism of isoniazid resistance. J. Antimicrob. Chemother. 64(3), 515-523 (2009).
3. Rieder HL. Drug-resistant tuberculosis: issues in epidemiology and challenges for public health. Tuber. Lung Dis. 75(5), 321-323 (1994). (Pubitemid 24336526)
4. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of antituberculosis drug resistance among children from the western Cape province of South Africa-An upward trend. Am. J. Public Health 99(8), 1486-1490 (2009).
5. Schaaf HS, Gie R P, Beyers N, Sirgel FA, de Klerk PJ, Donald PR. Primary drug-resistant tuberculosis in children. Int. J. Tuberc. Lung Dis. 4 (12), 1149-1155 (2000). (Pubitemid 32046293)
6. Feja K, McNelley E, Tran CS, Burzynski J, Saiman L. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr. Infect. Dis. J. 27(10), 907-912 (2008).
7. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int. J. Tuberc. Lung Dis. 8(5), 636-647 (2004). (Pubitemid 38625076)
8. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-Analysis. Lancet Infect. Dis. 12(6), 449-456 (2012).
9. Seddon JA, Hesseling AC, Marais BJ, Jordaan A, Victor T, Schaaf HS. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int. J. Tuberc. Lung Dis. 16(7), 928-933 (2012).
10. Thomas TA, Shenoi SV, Heysell SK et al. Extensively drug-resistant tuberculosis in children with human immunodefciency virus in rural South Africa. Int. J. Tuberc. Lung Dis. 14(10), 1244-1251 (2010).
11. Kjollerstrom P, Brito MJ, Gouveia C, Ferreira G, Varandas L. Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit. Scand. J. Infect. Dis. 43(6-7), 556-559 (2011).
12. Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int. J. Tuberc. Lung Dis. (2012) (Epub ahead of print).
13. Kurbatova EV, Cavanaugh JS, Shah NS et al. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int. J. Tuberc. Lung. Dis. 16(3), 355-357 (2012).
14. Mukinda FK, Theron D, van der Spuy GD et al. Rise in rifampicin- monoresistant tuberculosis in western Cape, South Africa. Int. J. Tuberc. Lung Dis. 16(2), 196-202 (2012).
15. Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int. J. Tuberc. Lung Dis. 16(1), 76-81 (2012).
16. Schaaf HS. Drug-resistant tuberculosis in children. S. Afr. Med. J. 97(10 Pt 2), 995-997 (2007). (Pubitemid 350027957)
17. Becerra MC, Appleton SC, Franke MF et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis. A retrospective cohort study. Lancet 377(9760), 147-152 (2011).
18. Grandjean L, Crossa A, Gilman RH et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int. J. Tuberc. Lung Dis. 15(9), 1164-1169 (2011).
19. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr. Respir. Rev. 12(1), 31-38 (2011).
20. Schaaf HS, Gie R P, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 109(5), 765-771 (2002). (Pubitemid 34493340)
21. Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 7(12 Suppl. 3), S501-S509 (2003). (Pubitemid 38004731)
22. Schaaf HS, Beyers N, Gie RP et al. Respiratory tuberculosis in childhood: the diagnostic value of clinical features and special investigations. Pediatr. Infect. Dis. J. 14(3), 189-194 (1995).
23. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confrmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 365(9454), 130-134 (2005). (Pubitemid 40091802)
24. Goussard P, Gie R P, Kling S, Beyers N. Expansile pneumonia in children caused by Mycobacterium tuberculosis: clinical, radiological, and bronchoscopic appearances. Pediatr. Pulmonol. 38(6), 451-455 (2004). (Pubitemid 39565217)
25. Vallejo JG, Ong LT, Starke Jr. Clinical features, diagnosis, and treatment of tuberculosis in infants. Pediatrics 94(1), 1-7 (1994). (Pubitemid 24194087)
26. Marais BJ, Hesseling AC, Gie R P, Schaaf HS, Enarson DA, Beyers N. The bacteriologic yield in children with intrathoracic tuberculosis. Clin. Infect. Dis. 42(8), e69-e71 (2006).
27. Nicol MP, Zar HJ. New specimens and laboratory diagnostics for childhood pulmonary TB. Progress and prospects. Paediatr. Respir. Rev. 12(1), 16-21 (2011).
28. Wright CA, Hesseling AC, Bamford C, Burgess SM, Warren R, Marais BJ. Fine-needle aspiration biopsy: a frst-line diagnostic procedure in paediatric tuberculosis suspects with peripheral lymphadenopathy? Int. J. Tuberc. Lung Dis. 13(11), 1373-1379 (2009).
29. Schaaf HS, Geldenduys A, Gie RP, Cotton MF. Culture-positive tuberculosis in human immunodefciency virus type 1-infected children. Pediatr. Infect. Dis. J. 17(7), 599-604 (1998). (Pubitemid 28340870)
30. Kiet VS, Lan NT, An DD et al. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48(8), 2934-2939 (2010).
31. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J. Clin. Microbiol. 49(12), 4138-4141 (2011).
32. Taylor N, Gaur RL, Baron EJ, Banaei N. Can a simple fotation method lower the limit of detection of Mycobacterium tuberculosis in extrapulmonary samples analyzed by the GeneXpert MTB/RIF assay? J. Clin. Microbiol. 50(7), 2272-2276 (2012).
33. Nicol MP, Workman L, Isaacs W et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect. Dis. 11(11), 819-824 (2011).
34. Schaaf HS, Moll A P, Dheda K. Multidrug-And extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clin. Chest Med. 30(4), 667-683, vii-viii (2009).
35. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 14(6), 672-682 (2010).
36. Mphahlele M, Syre H, Valvatne H et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46(10), 3459-3464 (2008).
37. Hoek KG, Schaaf HS, Gey van Pittius NC, van Helden PD, Warren RM. Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. S. Afr. Med. J. 99(11), 785-787 (2009).
38. Schaaf HS, Seddon JA, Caminero JA. Second-line antituberclosis drugs: current knowledge and controversies. Prog. Respir. Res. 40, 81-95 (2011).
39. Seddon JA, Hesseling AC, Marais BJ et al. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb.) 92(1), 9-17 (2012).
40. Forsythe CT, Ernst ME. Do fuoroquinolones commonly cause arthropathy in children? CJEM 9(6), 459-462 (2007).
41. Schaaf HS, Victor TC, Venter A et al. Ethionamide cross-And co-resistance in children with isoniazid-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 13(11), 1355-1359 (2009).
42. Brossier F, Veziris N, Jarlier V, Sougakoff W. Performance of MTBDRplus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int. J. Tuberc. Lung. Dis. 13(2), 260-265 (2009).
43. Van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182(5), 684-692 (2010).
44. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 12(2), 139-145 (2008). (Pubitemid 351212404)
45. Abdool Karim SS, Naidoo K, Grobler A et al. Integration of antiretroviral therapy with tuberculosis treatment. N. Engl. J. Med. 365(16), 1492-1501 (2011).
46. Coyne KM, Pozniak AL, Lamorde M, Boffto M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 23(4), 437-446 (2009).
47. Cilliers K, Labadarios D, Schaaf HS et al. Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid. Acta Paediatr. 99(5), 705-710 (2010).
48. Wiseman CA, Gie RP, Starke JR et al. A proposed comprehensive classifcation of tuberculosis disease severity in children. Pediatr. Infect. Dis. J. 31(4), 347-352 (2012).
49. Schaaf HS, Hesseling AC, Godfrey-Faussett P, Seddon JA. Experience with multidrug-resistant tuberculosis (MDR-TB) therapy in a cohort of South African children. Presented at: The 43rd Union World Conference on Lung Health. Kuala Lumpur, Malaysia, 13-17 November 2012.
50. Drobac PC, Mukherjee JS, Joseph JK et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 117(6), 2022-2029 (2006). (Pubitemid 46071247)
51. Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS. Culture-confrmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin. Infect. Dis. 54(2), 157-166 (2012).
52. Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S. Afr. Med. J. 102(6), 363-366 (2012).
53. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur. Respir. J. doi:10.1183/09031936.00044812 (2012) (Epub ahead of print).
54. Thee S, Zollner EW, Willemse M, Hesseling AC, Magdorf K, Schaaf HS. Abnormal thyroid function tests in children on ethionamide treatement (short communication). Int. J. Tuberc. Lung Dis. 15(9), 1191-1193 (2011).
55. Seddon JA, Visser DH, Bartens M et al. Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pediatr. Infect. Dis. J. 31(7), 711-716 (2012).
56. Padayatchi N, Bamber S, Dawood H, Bobat R. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatr. Infect. Dis. J. 25(2), 147-150 (2006). (Pubitemid 43208569)
57. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect. Dis. 12(6), 469-479 (2012).
58. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 54(RR-17), 1-141 (2005).
59. Munoz FM, Ong LT, Seavy D, Medina D, Correa A, Starke Jr. Tuberculosis among adult visitors of children with suspected tuberculosis and employees at a children's hospital. Infect. Control Hosp. Epidemiol. 23(10), 568-572 (2002). (Pubitemid 35168189)
60. Schaaf HS, Donald PR, Scott F. Maternal chest radiography as supporting evidence for the diagnosis of tuberculosis in childhood. J. Trop. Pediatr. 37(5), 223-225 (1991).
61. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008).
62. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56(6), 3271-3276 (2012).
63. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360(23), 2397-2405 (2009).
64. Diacon AH, Dawson R, du Bois J et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother. 56(6), 3027-3031 (2012).
65. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15(7), 949-954 (2011).
66. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung Dis. 16(8), 1005-1014 (2012).
67. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifoxacin combinations: a randomised trial. Lancet 380(9846), 986-993 (2012).
68. Lambert PH, Hawkridge T, Hanekom WA. New vaccines against tuberculosis. Clin. Chest Med. 30(4), 811-826, x (2009).
69. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin. Chest. Med. 30(4), 769-782, ix (2009).
70. Kassa-Kelembho E, Bobossi-Serengbe G, Takeng EC, Nambea-Koisse TB, Yapou F, Talarmin A. Surveillance of drug-resistant childhood tuberculosis in Bangui, Central African Republic. Int. J. Tuberc. Lung. Dis. 8(5), 574-578 (2004). (Pubitemid 38625062)
71. Morcos W, Morcos MM, Doss S, Naguib M, Eissa S. Drug-resistant tuberculosis in Egyptian children using Etest. Minerva Pediatr. 60(6), 1385-1392 (2008).
72. Rasolofo Razanamparany V, Ramarokoto H, Clouzeau J et al. Tuberculosis in children less than 11 years old: primary resistance and dominant genetic variants of Mycobacterium tuberculosis in Antananarivo. Arch. Inst Pasteur Madagascar 68(1-2), 41-43 (2002).
73. Ramarokoto H, Ratsirahonana O, Soares JL et al. First national survey of Mycobacterium tuberculosis drug resistance, Madagascar, 2005-2006. Int. J. Tuberc. Lung Dis. 14(6), 745-750 (2010).
74. Schaaf HS, Marais BJ, Hesseling AC, Gie R P, Beyers N, Donald PR. Childhood drug-resistant tuberculosis in the western Cape Province of South Africa. Acta Paediatr. 95(5), 523-528 (2006). (Pubitemid 43791572)
75. Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect. Dis. 11, 28 (2011).
76. Nelson LJ, Schneider E, Wells CD, Moore M. Epidemiology of childhood tuberculosis in the United States, 1993-2001: the need for continued vigilance. Pediatrics 114(2), 333-341 (2004). (Pubitemid 39006658)
77. Llerena C, Fadul SE, Garzon MC et al. Drug-resistant Mycobacterium tuberculosis in children under 15 years. Biomedica 30(3), 362-370 (2010).
78. Asencios L, Quispe N, Mendoza-Ticona A et al. [National surveillance of antituberculosis drug resistance, Peru 2005-2006]. Rev. Peru. Med. Exp. Salud Publica 26(3), 278-287 (2009).
79. Rekha B, Swaminathan S. Childhood tuberculosis-global epidemiology and the impact of HIV. Paediatr. Respir. Rev. 8(2), 99-106 (2007). (Pubitemid 46900103)
80. Lolekha R, Anuwatnonthakate A, Nateniyom S et al. Childhood TB epidemiology and treatment outcomes in Thailand: a TB active surveillance network, 2004 to 2006. BMC Infect. Dis. 8, 94 (2008).
81. Abubakar I, Laundy MT, French CE, Shingadia D. Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999-2006. Arch. Dis. Child. 93(12), 1017-1021 (2008).
82. Kanavaki S, Mantadakis E, Nikolaou S, Karambela S, Samonis G. Antimicrobial resistance of Mycobacterium tuberculosis isolates from children in Greece, 1994-2004. Int. J. Tuberc. Lung Dis. 11(4), 424-428 (2007). (Pubitemid 46595773)
83. Krogh K, Suren P, Mengshoel AT, Brandtzaeg P. Tuberculosis among children in Oslo, Norway, from 1998 to 2009. Scand. J. Infect. Dis. 42(11-12), 866-872 (2010).
84. Nejat S, Buxbaum C, Eriksson M, Pergert M, Bennet R. Pediatric tuberculosis in Stockholm: a mirror to the world. Pediatr. Infect. Dis. J. 31(3), 224-227 (2012).
85. McIlleron H. Tuberculosis drug information. In: Tuberculosis. A Comprehensive Clinical Reference. Schaaf HS, Zumla A (Eds). Saunders Elsevier, London, UK, 958-971 (2009).
86. Chien S, Wells TG, Blumer JL et al. Levofoxacin pharmacokinetics in children. J. Clin. Pharmacol. 45(2), 153-160 (2005).
87. Li F, Nandy P, Chien S, Noel GJ, Tornoe CW. Pharmacometrics-based dose selection of levofoxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob. Agents Chemother. 54(1), 375-379 (2010).